Ureteral stent for improved patient comfort

Information

  • Patent Grant
  • 8845752
  • Patent Number
    8,845,752
  • Date Filed
    Thursday, July 26, 2012
    12 years ago
  • Date Issued
    Tuesday, September 30, 2014
    10 years ago
Abstract
A ureteral stent for assisting the movement of urine along a patient's ureter and into the patient's bladder. The stent includes an elongated tubular segment extending toward the bladder from a kidney end region for placement in the renal cavity to a bladder end region. A central lumen connects at least one opening at the first end region to at least one opening in the bladder end region. Thin flexible tail(s) are attached to the bladder end region of the tubular segment at a point outside the bladder so as to receive urine from the opening in the bladder end region of the tubular segment and to transport urine from there across the ureter/bladder junction and into the bladder.
Description
TECHNICAL FIELD

This application relates generally to medical devices for drainage of fluids, and more specifically to ureteral stents.


BACKGROUND

Ureteral stents are used to assist urinary drainage from the kidney to the bladder in patients with ureteral obstruction or injury, or to protect the integrity of the ureter in a variety of surgical manipulations. More specifically, stents may be used to treat or avoid ureter obstructions (such as ureteral stones or ureteral tumors) which disrupt the flow of urine from the kidneys to the bladder. Serious obstructions may cause urine to back up into the kidneys, threatening renal function. Ureteral stents may also be used after endoscopic inspection of the ureter.


Ureteral stents typically are tubular in shape, terminating in two opposing ends: a kidney (upper) end and a bladder (lower) end. The ends may be coiled in a pigtail or J-shape to prevent the upward or downward migration of the stent, e.g., with physiological movements. A kidney coil can function as a distal retention structure, designed to retain the stent within the renal pelvis of the kidney and to prevent stent migration down the ureter. The bladder coil sits in the bladder and is designed to prevent stent migration upward toward the kidney. The bladder coil is also used to aid in retrieval and removal of the stent.


Ureteral stents, particularly the portion positioned in the ureter near the bladder and inside the bladder, may produce adverse effects including blood in the urine, a continual urge to urinate, strangury, and flank pain accompanying reflux of urine up the stent (e.g., when voiding) as pressure within the bladder is transmitted to the kidney. In short, stents may cause or contribute to significant patient discomfort and serious medical problems.



FIG. 10 is a schematic drawing of the human urinary tract without a stent, showing the renal pelvis 19, the kidney 23, the ureter 24, and the ureteral orifices 18 opening into the bladder 20. FIG. 11 depicts a typical double-J stent 10 which comprises a small tube 12 which sits inside the urinary system and assists the flow of urine from the kidney (renal pelvis) to the bladder. FIG. 12 depicts prior art indwelling ureteral stent 10 in position. Such stents are typically made of biocompatible plastic, coated plastic, or silicone material. Tube 12 typically varies in size from 4-8 F, and it has multiple small holes throughout its length. A coiled shape pre-formed at each end (distal end 14 and proximal end 16) of the stent 10 is designed to confine its movement within the urinary system, so that it will be maintained in the desired position. The upper (kidney) end (the distal end 14) of the stent can include a distal retention structure 104. The distal end 14 may be closed or tapered, depending on the method of insertion (e.g., the use of a guidewire). The tubular stent extends through the ureteral orifice 18a and into the bladder, fixing orifice 18a open, and thereby enhancing the opportunity for reflux. For clarity, the ureter entering bladder 20 through orifice 18b is not shown. A monofilament thread 22 may be attached to the bladder end of the stent for removal, usually without cystoendoscopy.


U.S. Pat. No. 4,531,933 (“the '933 patent”) discloses a ureteral stent having helical coils at each end which are provided for preventing migration and expulsion.


SUMMARY OF THE INVENTION

We have discovered a ureteral stent design that avoids patient discomfort and urine reflux upward toward the kidney. Rather than rely on a tubular structure to contain and facilitate all (or, in some embodiments, any) urine flow along the ureter, the invention features a thin, flexible elongated tail member having an elongated external urine-transport surface. Urine flows along the outside surface of the structure, between that surface and the inside wall of the ureter. Without limiting ourselves to a specific mechanism, it appears that urine may remain attached to, and flow along, the external urine transport surface. The use of a foreign body that is as small as possible in the lower (bladder) end of the ureter and in the bladder itself decreases patient discomfort. Typically, the external urine transport surface is sized and configured to extend along at least part of the ureter near the bladder, across the ureter/bladder junction, and from there through the ureteral opening into the bladder.


While most or all of the length of the stent may rely on such an external surface to assist flow, more typically the stent will also include an upper elongated tubular segment to transport urine along a significant portion of the upper ureter. The upper tubular segment is connected at its lower end to an elongated tail that has the above-described external urine-transport surface. The upper tubular segment comprises: a) an upper region having at least a first opening; b) a lower region having at least a second opening to be positioned in the ureter outside the bladder, and c) a central lumen connecting the first opening to the second opening. The elongated tail is a thin flexible tail member or filament(s) extending from the lower region of the tubular segment at a point outside the bladder so as to receive urine from the second opening of the tubular segment and to transport urine along the ureter from the lower region of the tubular segment across the ureter bladder junction and into the bladder. Typically, but not exclusively, the upper region of the tubular segment is configured and sized for placement in the renal cavity.


The elongated tail member can include at least one (and more preferably at least two) thread filaments(s). Two or more of the filaments may be configured in at least one filament loop, and, advantageously, the tail comprises no unlooped filaments, so that the tail is free from loose ends. The loop(s) can be made by joining the ends of a single filament, in which case the filament loop comprises a junction of individual filament ends, which junction typically is positioned at the point where tail joins to the elongated tubular segment. Preferably, the tail is long enough to effectively prevent migration of the entire tail into the ureter, and the tail has a smaller outer diameter than the outer diameter of the tubular segment.


The tubular stent segment can be stiff enough to avoid crimping during insertion through the ureter, so that it can be inserted by typical procedures. The tail, on the other hand, can be extremely flexible (soft) in comparison to the tubular segment, and it can have a much smaller diameter than the tubular segment, to avoid discomfort. Even quite thin structures can provide urine transport, and the thinner and more flexible the tail is, the less likely it is to cause patient discomfort. On the other hand, the tail (and its connection to the rest of the stent) should have sufficient strength so the stent can be retrieved by locating the tail in the bladder and pulling on the tail to retrieve the stent from the kidney and ureter. Details of the tail size are discussed below. The use of reinforcing materials (e.g., sutures as described below) permits the use of thinner tails while still providing the ability to locate the tail in the bladder and to retrieve the stent. The tail may be a suture, and the suture may be coated to avoid encrusting.


The external urine-transport surface of the tail can be convex (circular or oval in section), concave, or flat. The tail filament may be fluted. The tail can include an accurately shaped anchor segment to control migration up the ureter. The tail may be either solid or hollow; even when hollow; it is not designed to transport a significant amount of urine internally. The tail may also be tapered.


The upper region of the tubular segment may have a portion designed for placement in the renal cavity, which portion can have an enlarged diameter and/or straight sides and comers. The stent may include an extractor thread attached to the lower end of the elongated tail member.


To make the stent, the tail may be molded in one piece with the tubular segment, or it may be made separately and attached to the bladder end region of the tubular segment at a point toward the kidney from the bladder end of the lower region of the tubular segment. In one embodiment, the tail can be attached near or at the bladder end of the bladder end region of the tubular segment. The stent may include a suture securing the tail to the tubular segment, and the suture may be incorporated into the tail to impart strength to the tail so the tail may be used to retrieve the stent. If the tail includes a hollow lumen, the suture may be positioned inside that lumen. The suture may be attached to the tubular segment at a point in the bladder end region of the tubular segment, and the suture may extend from the point of attachment through an opening in the bladder end region to the central lumen of the tubular segment and from there to the hollow tail. Alternatively, at least the bladder end region of the tubular segment may include two lumens, a main urine-transporting lumen, and a bladder lumen to encase the suture, so that the suture does not become encrusted.


The outer diameter of the tubular segment can be tapered so that it decreases approaching its lower region. The lower region of the tubular segment may include multiple openings positioned, e.g., axially along include its length or radially around its circumference, or in other patterns. In addition, the outer diameter of the stent's tubular segment may decrease approaching the upper region. In other words, the maximum diameter may be at the site of the injury to encourage a sufficiently large inner diameter in the repaired structure, and the tubular segment's outer diameter may decrease moving away from that point of maximum diameter to sections of the normal ureter that are not in need of a broad support structure. Generally, the outer diameter of the upper end of the tubular segment will be greater than the other diameter of the bladder end. The upper region may include multiple openings (inlets).


In an alternative embodiment, the elongated external urine-transport surface is a continuous surface extending from the kidney to the bladder, e.g., it is the outer surface of a solid member extending from the kidney to the bladder.


Another aspect of the invention features a method of introducing a ureteral stent (described above) into a patient, by (a) positioning the kidney end region of the tubular segment within the renal pelvis; and (b) positioning the elongated flexible member(s) in the bladder.


Yet another aspect of the invention features a method of manufacturing a ureteral stent as described above. The method comprises: (a) providing a polymer perform having a tubular shape; (b) forming an elongated tubular stent segment from the polymer pre-form, and (c) providing tail member(s) at an end region of the tubular segment.


Another aspect of the invention relates to a ureteral stent comprising a distal region that includes a tubular body defining a lumen, and a distal retention structure. The distal retention structure maintains a position of the ureteral stent within the body with respect to a kidney. The ureteral stent also includes a proximal region in fluid communication with the distal region and including a distal portion that includes a junction with the distal region. The proximal region can comprise a pliable portion disposable within a ureteral orifice and in communication with the distal portion. The pliable portion is compressible upon the exertion of a body pressure, such as a pressure exerted by the ureteral orifice. The proximal region can also include a proximal portion that comprises one or more flexible filaments. The filament(s) form at least one loop that has a length sufficient to remain within the bladder when the distal retention structure is positioned within the kidney, but the length is insufficient to allow the loop to substantially contact the urethra.


Embodiments of this aspect of the invention include filaments that have a retention force insufficient to maintain the ureteral stent within the bladder. The pliable portion of the stent can extend distally from the ureteral orifice about 3 centimeters or more, and the pliable portion can include a soft section of tube or soft section of the stent compared to other sections of the stent, that is compressible by body pressure. In some embodiments the pliable portion includes a distal end of the plurality of the filaments. Upon exertion of the pressure, the pliable portion can collapse sufficiently to inhibit urine reflux.


Other embodiments include filaments that are sufficiently resilient to provide drainage (e.g., of urine) through an interstitial space. The interstitial space can be defined by the filaments and can be in fluid communication with the lumen of the distal region. The interstitial space, can be at least partially collapsible by body pressure. An embodiment includes at least one loop that is formed from a continuous filament. Two or more loops can be formed, and each loop can be formed from a single filament.


In other embodiments, the pliable portion can include a distal end of the filaments, and the filaments can be configured to minimize any sharp edges at the junction. The proximal region can be integrally formed with the distal region, and the distal region can have a hardness that is greater than the hardness of the proximal region. In some embodiments the hardness of the stent gradually decreases from a distal location of the distal region to a proximal location of the proximal region. The distal region typically has a hardness value of at least about 80-110 Shore A, although some embodiments can include a distal region with a hardness of about 60-80 Shore A. The proximal region can have a hardness of about 60-80 Shore A.


The length of loops formed by the filament(s) can be sufficient to maintain at least a portion of the stent within the bladder after intubation of the stent, including upon routine movement of the kidney and the bladder. The filaments can also have sufficient tensile strength to provide for extubation of the stent via the bladder or urethra. The ureteral stent can include a lubricious coating, and the tubular body of the stent can include one or more openings disposed along its length.


Another aspect of the invention relates to a ureteral stent comprising a distal region that includes a tubular body defining a lumen, and a distal retention structure. The distal retention structure maintains a position of the ureteral stent within the body. The stent also includes a proximal region in communication with the distal region. A portion of the proximal region is disposable within a ureteral orifice and includes a plurality of flexible filaments compressible upon the exertion of a body pressure, such as by a ureteral orifice. The filaments form at least one loop and have a length sufficient to remain within the bladder when the distal retention structure is positioned within the kidney, but the length is insufficient to allow the loop to substantially contact the prostatic urethra.


Yet another aspect of the invention features a medical device comprising a distal region that includes a tubular body defining a longitudinal axis and at least one lumen, the distal region including a distal retention structure. The medical device also includes a proximal region in fluid communication with the distal region, the proximal region comprising a distal portion and a proximal portion. The proximal portion includes at least two filaments forming at least two loops that define an interstitial space. The interstitial space is in fluid communication with the lumen. The loops are flexible, such that a pressure of the body can compress the interstitial space. The medical device has a hardness that gradually decreases from a distal location of the distal region to a proximal location of the proximal region.


As described in greater detail below, the stent may be manufactured from a polymer form having a tubular shape by forcing the form onto a mandrel to produce the desired three-dimensional shape (coils, etc.). The elongated tail member(s) or filament(s) can be attached to one end of the tubular member(s) using sutures as described above. Heat treatments to fuse the structures and/or standard adhesives may be used. Alternatively, the tubular member(s) and the elongated member or filament(s) can be integrally formed, constituting a one-piece stent.


The use of relatively thin, flexible elongated member(s) or filament(s) to assist urine flow across the uretero-vesical junction and into the bladder may reduce reflux and irritation, thereby reducing patient discomfort and medical problems associated with other types of ureteral stents.


Other features and advantages of the invention will appear from the following description of the preferred embodiment, and from the claims.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a side view of a ureteral stent with a central portion of the tubular segment omitted.



FIG. 2 is a cross-sectional view along line 2-2 in FIG. 1.



FIG. 3 is an enlarged side-view of a portion of the ureteral stent in FIG. 1.



FIG. 4A is a view of an alternate embodiment of the stent in FIG. 1, and FIG. 4B is a section taken along 4B-4B of FIG. 4A.



FIGS. 5A and 5B are schematic representations of another stent according to the invention, depicted in place.



FIGS. 6A-6D depict alternative cross-sections of the tail of a stent according to FIG. 5



FIG. 7 is a schematic representation of yet another stent according to the invention, having an extraction thread.



FIG. 7A is an enlargement of a portion of FIG. 7.



FIG. 8 is a schematic representation of the stent of FIG. 7 shown in position.



FIG. 8A is a detail of the connection between the tail and the extraction thread.



FIG. 8B is a cross-section of threads of differing softness, showing the effect of compression on interstitial space.



FIG. 9 shows an alternative embodiment of the stent.



FIG. 10 is a schematic drawing of the human urinary tract without a stent, showing the renal pelvis, the kidney, the ureter, and the ureteral orifices opening into the bladder.



FIG. 11 depicts a prior art double-J stent outside the body.



FIG. 12 depicts a prior art J indwelling ureteral stent in position.



FIG. 13 illustrates an embodiment of a ureteral stent of the invention comprising a proximal region including a loop formed from one or more flexible filament(s).



FIG. 13A is an exploded view of a portion of the embodiment of a ureteral stent shown at 13A in FIG. 13.



FIGS. 14 and 14A depict an embodiment of a ureteral stent including a pliable portion.



FIGS. 15, 15 A, 15B, 15C, 15C′, and 15C″ illustrate embodiments of ureteral stents including a pliable portion, in which the pliable portion includes loops with one or more flexible filament(s).



FIGS. 16A-16B illustrate general placement in the body of embodiments of ureteral stents comprising loops formed of one or more flexible filament(s).





DETAILED DESCRIPTION

In FIG. 1, ureteral stent 100 includes an elongated tubular body 130 connecting coil end 140 to straight end region 120. Tubular body 130 is designed to extend from the renal pelvis through the ureter to a terminus upstream of the bladder. Tail 110 is attached to straight end region 120, and tail 110 extends along the ureter, across the ureter/bladder junction and into the bladder.


The two opposing end regions 120 and 140 of elongated tubular body 130 are illustrated in FIG. 1. Coiled end region 140 is designed to be placed in the renal pelvis of the kidney. For illustrative purposes, coiled end region 140 is shown with a pigtail helical coil although any shape that will retain the stent in place within the kidney will do. Coiled end region 140 includes several openings 125 placed along the wall of the tubular body; the openings may be arranged in various geometries (e.g., axial, circumferential, spiral). The entire tubular segment, including the region between the kidney and the bladder end regions, may include additional openings.


The bladder end region 120 of the tubular stent segment is designed to terminate in the ureter, upstream of the bladder. For purposes of further description, the end region of stent 100 received in the kidney will be designated the kidney end and the opposite end of stent 100 toward the bladder will be termed the bladder end.



FIG. 2 is a cross-sectional view of stent 100 of FIG. 1. In FIG. 2, elongated tubular body 130 has annular walls 250 having an inner and outer diameter. The outer diameter of tubular body 130 may be substantially uniform throughout much of the length of the tube, or it may taper from a relatively short region of larger diameter (the site of the repair, where there is a risk that the healing process will substantially restrict flow in the lumen) to a region of generally small diameter. The precise configuration may depend on the ureteral defect being corrected. Just one of the many classes of procedures that can benefit from the stent are endopyelotomies—procedures for treating ureteropelvic junction (UPJ) obstruction by an incision which perforates the ureter at the stricture. In these and other procedures, the stent keeps the ureter lumen open during the healing process, so that the inner diameter of the resulting healed structure is adequate. The section of the tubular segment at the defect is large enough to support growth of repair tissue having an adequate inner diameter. At other sections of the ureter (e.g., sections not being surgically repaired), the outer diameter of the tubular segment may be far smaller, but with an inner diameter adequate for passage over a guidewire. For example, the outer diameter of the bladder end region of the tubular segment typically is 2 F-12 F. Preferably the outer diameter of tubular body 130 is greatest at the ureteropelvic junction obstruction but begins to taper approaching each end. Alternatively, for a patient with an upper ureteral obstruction, the upper (kidney) portion of the tubular body 130 may be uniform in diameter, tapering just in the lower (bladder) portion.


Tubular body 130 defines a central lumen or passageway 260, extending from kidney end region 140 to bladder end region 120. The inner diameter of lumen 260 is sufficient to permit passage over a guidewire. Tubular body 130 may also have openings 125 extending through its walls 250 to facilitate the flow of urine from the kidney into central lumen 260 and openings 127 to facilitate flow out of central lumen 260.


In FIG. 3, the outer diameter of elongated tubular body 130 tapers near bladder end region 120. The outer diameter of bladder end region 120 may be made as small as possible while maintaining the ability to pass over a guidewire. Elongated tubular body 130 may (but need not be) substantially straight in bladder end region 120, i.e. it does not coil or curve in the absence of external force. When tail 110 is a single filament, it typically is thinner than even the smallest portion of bladder end region 120 of the tubular stent segment. Alternatively, it may be desirable to design the tail from multiple filaments, each of which, by itself, is much thinner than the bladder end region of the tubular stent segment. Together, such a multi-filament tail has a larger effective diameter, providing additional bulk while maintaining comfort. Tail 110 may be attached at or near the end of region 120, and it extends from that attachment into the bladder. Tail 110 can be either solid or hollow. It can be generally cylindrical in shape; alternatively, it can be fluted, concave (quartermoon)-shaped or it may assume other shapes.


The tail can have an outer diameter that is significantly less than the inner diameter of the ureter (typically 2-5 mm) and no greater than the outer diameter of the tubular segment from which it extends. For example, the tail diameter can be less than 10 F and as low as a suture (about 0.5 F). Preferably the tail diameter is between 2 F and 4 F. The length of tail 110 is preferably between 1 and 100 cm. In one embodiment, the tail is long enough so that at least a portion of it will remain in the bladder, and effectively the entire tail cannot migrate up into the ureter. A length of between 1 and 40 cm can be effective for this purpose. Tail 110 is flexible and, upon application of force, can be curved, but also has memory such that when the force is removed, it is generally straight.


Stent 100, including tail 110 and tube 130, may be a single unit. Thus, tail 110 can be a unified piece, extending from bladder end region 120 with no additional attachment means. Alternatively tail 110 can be secured to elongated tube 130 or bladder end region 120 by physical or mechanical methods.


As shown in FIG. 4A, a suture 415 can be inserted through an opening 418 in the tubular member and then threaded through the lumen 417 of tubular member 430. In FIG. 4B, tail 410 is a hollow member having suture 415 threaded through its inner lumen 412.



FIG. 5 is a schematic of another stent 510. The kidney end A of the stent has a pre-formed memory bend, to coil 512 as shown. Kidney end A is larger and more rectangular to help prevent upward as well as downward stent migration. End A may be closed or tapered to accommodate various insertion techniques. For the upper portion (A-B) of the stent, diameter, lumen size, perforations and materials are conventional. The lower end 514 of the tubular stent segment ends at B. The distance A-B could vary depending on the patient's anatomy. At B, the stent is tapered (or at least smooth and constant in diameter).


Two or more monofilament or coated (plastic or silicone) threads 516 exit from the lumen or from the stent wall. These threads only partially fill the ureter and are as flexible (soft) as possible. Typically, they are cut to a length that forces confinement within the bladder.


The portion of the upper segment 512 lying within the renal pelvis (e.g., from the kidney end of the stent to point A) is expanded so that it is larger in section, and it may even be oval or rectangular in cross-section, to help prevent upward as well as downward stent migration. The kidney end of the stent may be closed and/or tapered to accommodate the desired insertion technique. The upper portion 512 is made of a relatively stiff material (among the materials currently used in ureteral stents), and it should be designed to effectively restrict the motion of the stent to prevent proximal as well as distal migration of the catheter during normal physiological activity (required because the lower pre-formed portion is deleted). The length of the straight portion of the upper segment (FIG. 5A point A to B) will vary with patient size and anatomy. In the preferred configuration, the upper segment extends more than halfway down the ureter when in proper position. The lowest end of the upper segment (Fig. SA point B) should be tapered or beveled to facilitate withdrawal. Otherwise, the upper segment is a typical stent in diameter, materials, and shape.


The lower segment (FIG. 5A point B to point C) consists of two or more (e.g., four) monofilament, plastic coated or silicone coated threads (shown in section in FIG. 5B) which extend from the lumen or sidewall of the lower end of the upper segment (FIG. 5A point B) along ureter 513 into the bladder. These threads are extremely flexible, and their diameter is selected to maintain a passage for urine flow and yet drastically reduce bladder and ureteral irritation. By avoiding distortion of the ureter wall, the threads may inhibit urinary reflux as well. The threads should be long enough to reach well into the bladder (FIG. 5A point C), but not so long as to wash into the urethra with voiding. One thread 518 (or two or more threads in a loop) may be long enough to exit through the urethra (FIG. 5A point B to point D) to permit ready removal by pulling (avoiding cystoendoscopy).


These extended threads may also be used for stent exchange, in which a second catheter is exchanged for the catheter already in place. According to that procedure, these extended threads are captured with a snare that has been inserted through the central lumen of a second catheter. The snare is used to pull the threads through the lumen as the second catheter is advanced into the ureter. A guidewire is then inserted through the central lumen of the second catheter to the kidney (outside the first catheter's tubular body). The first stent can then be removed by pulling on the threads, leaving the guidewire in position for placement of a new stent using standard techniques.



FIGS. 6A-6D are alternative cross sectional sketches (taken at the same location as FIG. 5B) of some possible arrays of threads passing within the lower ureter 517. Multiple threads 516 (2 and 4, respectively) are shown in FIGS. 6A and 6B. A substantially similar conduit could be achieved by fluted type cross sections in a single filament FIGS. 6C and 6D). The shapes of FIGS. 6C and 6D could also be effective in reducing stiffness and hence irritability at the bladder end (I.e., lower segment), e.g., in a single filament design. Multiple threads may have the advantage of better surgical manipulability and superior comfort to the patient.


Further refinements are described below and in FIGS. 7 and 7A which deal with: a) proximal or upward stent migration of either the entire stent or individual threads in the lower segment independent of upper segment movement; b) bunching of one or more threads within the ureter so as to obstruct flow or cause ureteral injury or knotting at the time of removal; and c) in multi-thread embodiments, discomfort and/or reduced drainage through the ureter resulting from the use of threads of different lengths. In FIG. 7, a 6 F stent is depicted, which is generally a good size for adult urinary systems. It is large enough to provide good drainage and small enough to minimize local irritation and inflammation of the ureter. In this embodiment, the upper segment need be only a single loop of conventional size because a change in the design of the lower segment (see later discussion and FIG. 8) should prevent proximal migration. The upper segment (FIG. 7 point A to point C) is constructed of a relatively firm material because, during insertion, the pusher tubing should be removed after the guidewire is removed. This means that there will be some drag on the threads during removal of the pusher tubing which could dislodge the stent if the coil (FIG. 7 point A to point B, about 2.5 cm) does not provide adequate resistance. The coil may be tapered or closed depending on the insertion technique desired (i.e., over a previously placed guidewire).



FIG. 7 point B to point C can have an approximate length of 12 cm. This is long enough to prevent dislocation of the upper segment in a large renal pelvis and short enough to end well above the point where the ureter crosses the common iliac vessels. At the iliac vessels, the ureter takes a fairly sharp turn and the threads will more easily follow the natural curves at this point. This design should reduce the inflammation that is normally seen in this region when a conventional double-1 stent is left indwelling on a chronic basis.


The junction of the upper and lower segments at FIG. 7 point C is important. See FIG. 7 A, which enlarges this junction. At point C (FIG. 7) the threads are attached to the upper segment in a manner that achieves the following goals: 1) the threads are securely attached to the upper segment and to each other (at least for a short distance of about 0.8 mm) so that their orientation to themselves is maintained (to the maintenance of lower end asymmetry); 2) the threads do not obstruct the lumen of the upper segment and they allow for the easy passage of a standard guidewire (e.g., 0.035 guidewire); 3) the transition diameters in this region closely preserve the 6 F standard so that this point can pass in both directions smoothly throughout the instruments used for insertion and through the ureter; 4) there is no cause for a localized ureteral obstruction; and 5) there is an effective abutment for the pusher tubing. For an average size ureter a good starting string diameter for a four string lower segment (FIG. 7 point C to point E) would be 0.020 inches. A simple monofilament nylon thread is an easy potential solution but may be too stiff. A more supple monofilament or woven thread with silicone or other coating may be required to achieve minimal irritability. However, the threads can be sufficiently resistant to compression so that tissue-generated pressures cannot collapse the interspaces of the threads. See FIG. 8B, showing cross-sections of threads (left) which retain interstitial space under some modest compression, and of threads (right) which are so soft that they compress into a plug with reduced interstitial space. These threads may have centimeter markings beginning at a point no more than 20 centimeters from point B (FIG. 7) so that functional ureteral and total stent length may be noted.


The portion of the lower segment that lies within the bladder when the stent is in proper anatomic position (FIG. 7 point D to point E) is important to both comfort and function. Proximal migration can be controlled by using asymmetrical lengths of the thread pairs, with one pair being 2 cm longer that the other pair, so that the fused junction 810 of these threads tends to intersect with the ureteral orifice 18 at an angle (e.g., ˜90°) with the stiffened area 815 having a length of 6 mm (see detail FIG. 8A). In the ideally fitted stent of this embodiment, the thread pairs will extend beyond the ureteral orifice (FIG. 7 point D) by 1 cm at the short limb 820 and 3 cm at the long limb 825. However, this lower segment configuration allows for considerable tolerance in sizing (unlike unsecured independent threads which must be selected to have a length so as to avoid upward migration of the thread through the ureteral orifice 18) and a chosen length which is 1 cm shorter or 2-3 cm longer than the ideal length should be satisfactory. Using this configuration the threads should form a continuous loop 828 of 3.5 cm length to prevent free ends from poking the bladder wall or prolapsing through the urethra. Buoyant threads may add to patient comfort, because they will float away from the trigone region of the bladder, where most of the sensory nerve fibers are located. A typical small gauge filament extraction thread 830 may be attached to the longer limb 825 of the thread pairs, which is a suitable pulling point for removal.


From this embodiment, a small diameter pusher tubing of 4-4.5 F should be used to aid insertion. Soft Percuflex® material can be used for the lower segment and firm or regular Percuflex® can be used for the upper segment.


The bladder end should be easily inserted using instruments, and it should prevent proximal migration of the stent. The design of FIG. 7 will avoid tangling and migration of the stent. Alternatively, soft Percuflex® material, for example, has good resistance to extreme flexion at small radii (e.g., even 0.020″ diameter) so that a simple continuous loop extending from the junction of the upper and lower segments (see FIG. 9) may be adequate to prevent upward migration. The design of FIG. 9 also has the advantage of relative ease of manufacture and relative ease of insertion, as well as ease and comfort of removal.


Other dimensions that can be used (without limitation) are 12 cm straight portion of the upper hollow shaft, and 12 cm, 14 cm, or 16 cm length of added loops of soft Percuflex@ material. For material with a 0.020″ diameter, either 2 or 3 loops may be used, providing 4 or 6 strings, total. For 0.040″ inch material, either 1 or 2 loops is recommended.



FIG. 9 shows such an alternative embodiment having a simple coil at the kidney end. The lower end is constructed of looped stringlike elements with ends fused at the junction between the lower and the upper end. Therefore, there are even numbers of string elements, with no free ends. Circle E in FIG. 9 represents an idealized depiction of the ureteral opening into the bladder. While not shown in FIG. 9, the loops may be fused over a very short distance at the bladder end in order to prevent tangling of loops and to improve stent handling. Any conventional means of fusion may be used. Optionally, organization of the loops can be maintained by pre-placing them inside the pusher tubing using a long monofilament nylon loop tail, similar to those used for the non-invasive removal stents (i.e. without sensor endoscopy).


Methods for insertion and removal of ureteral stents are known in the art. Generally, stent placement is achieved by advancing the tubular stent segment over a guidewire in the ureter. A pushing catheter passes the tubular segment into the kidney, while maintaining the tail in the bladder. Other methods such as a stiff sheath can be used to position the stent. Once in position, the sheath can be removed.


Another embodiment of the invention features a proximal region 106 comprising threads or filaments 111 as illustrated in FIG. 13. The fine flexible filaments 111 can be connected proximally to form a loop 118, or the loop can be formed from a continuous filament. The filaments have a small diameter, e.g., 3 French or less (i.e., less than, about 0.040 inches in diameter). In one configuration individual filaments preferably have no internal lumen. The illustrated embodiment includes a distal region 102 that includes a tubular body 130 having openings 125 and defining a lumen 260 therein. The proximal region 106 can be integrally formed with distal region 102. A distal portion of the distal region 102 includes a distal retention structure 104, configured to maintain placement of the distal end of the stent within a renal pelvis 19. As illustrated in FIG. 13A, an interstitial space 131 is defined between the filaments. The interstitial space 131 is in fluid communication with lumen 260 of the tubular body 130. The interstitial space provides for drainage, e.g., of urine, from the kidney (e.g., the renal pelvis 19) through the lumen 260 of the tubular body 130 and into the bladder 20 of a patient's body. Such drainage can occur in the space between the filaments 111 and/or along surfaces of the filaments.



FIG. 14 depicts an embodiment of a ureteral stent having a proximal region 106 that includes a plurality of loops. The proximal portion 137 of the proximal region 106 includes loops 118 fanned from one continuous filament, or, alternatively, the loops 118 can be formed from at least a portion of a plurality of filaments 111. In the illustrated embodiment, the proximal region includes two loops 118 formed from two continuous filaments 111. In an alternative embodiment, the proximal region includes two loops 118 formed from a portion of four filaments. Each loop is formed of at least two filaments, preferably by joining the proximal ends of two filaments together. A pliable portion 135 is disposed adjacent to the proximal portion 137, and can comprise a soft portion of tube compressible by pressure (e.g., body pressure). The filaments 111 are configured to minimize any sharp exterior edges at the interface between the filaments and the pliable portion 135. In some embodiments, the lumen 260 of the tubular body 130 extends through to the pliable portion 135, as illustrated. The proximal region 106 also includes a distal portion 133 comprising a junction 134 between the pliable portion 135 and the distal region 102. The pliable portion can be a distinct section of tube incorporated into the stent, or the pliable portion can be a section of the stent that is integral with the distal region. Preferably, the pliable portion is softer than distal portions of the stent along the distal region.


The filaments 111 of the proximal portion 137 define an interstitial space 131. Interstitial space 131 is in fluid communication with lumen 260, and provides for flow between the kidney and the bladder 20.


As illustrated in FIG. 14A, the pliable portion 135 is compressible upon exertion of a pressure by the body, such as a pressure exerted by the ureteral orifice 18. Preferably, the stent is positioned within the body such that the pliable portion 135 is located at or near the ureteral orifice 18. In one embodiment, the pliable portion 135 extends distally into the ureter for a distance of approximately 2-3 centimeters (e.g., FIG. 16B). The pliable portion 135 of this embodiment can extend through the ureteral orifice 18 and into the bladder (e.g., FIG. 16A). In such embodiments, the overall loop length can be 3-6 centimeters with no portion of the loop residing in the proximal 2-3 cm of the ureter. This proximal portion of the ureter is believed to be highly innervated. Contact of this portion of the ureter with the softer material of the pliable portion provides increased comfort to the patient.


Constriction of the ureteral orifice by the patient can exert a pressure on the pliable portion 135 resulting in constriction of the pliable portion, thereby reducing or eliminating the flow area available in the portion of the lumen 260 disposed within the pliable portion. This reduction in flow area reduces or eliminates painful urine reflux that can be experienced by the patient. In this way, the pliable portion can collapse sufficiently to inhibit urine reflux. When the body pressure is removed, the pliable portion reopens.


In one embodiment, the overall length of the loops 118 in FIGS. 14 and 14A can be about 4-6 centimeters. For example, a loop with a length of 5 centimeters can be formed from a single filament 111 having a length of about 10 centimeters, or from two filaments 111 each having a length of about 5 centimeters. The loop 118 is designed to be sufficiently long to remain in the bladder 20 when the distal retention structure 104 is positioned within the kidney. At the same time, the length of the filaments should be short enough to substantially reduce contact of the loop with the urethra 123. As stated previously, contact with the urethral opening can cause patient discomfort. Although incidental contact can generally be tolerated by a patient, extensive contact of a loop or filament across the bladder neck or into the urethra can cause extreme discomfort. This contact can also result in obstruction of the flow of urine from the bladder through the prostatic urethra during voiding. Moreover, routine movement of the kidney and the bladder can result in corresponding relative motion along the stent length of about 2 centimeters. Proper sizing of the length of the filament loops provides effective compensation for this movement. The length of the loop can be established to maintain at least a portion of the loop within the bladder after intubation, including upon routine movement of the kidney and the bladder. By way of example, a loop length of approximately 5 centimeters can be effective for this purpose.


Contact of any portion of the proximal region 106 with the trigone can cause patient discomfort. Such contact should be minimized or eliminated. Embodiments of the invention accomplish this by providing no significant retention force for the stent within the bladder 20. That is, the filaments have a retention force insufficient to maintain the stent within the bladder. The flexible filaments are designed to free float within the bladder, making little or no contact with the trigone. Such contact is also minimized by having no stiffened or rigid areas within or about the filaments, and by minimizing their diameter, volume, surface area, and mass. Although the distal region of the stent can have a hardness of about 110 Shore A, the proximal region is generally much softer, having a Durometer hardness of approximately 60-80 Shore A. In some embodiments the hardness of the stent is gradually decreased from a distal location, e.g., 141, of the distal region to a proximal location, e.g., 142, of the proximal region. Preferably, the proximal region is integrally formed with the distal region in such embodiments.


The lower hardness limit (i.e., the softness limit) of the filaments can be determined by the tensile strength required to withdraw the stent from the body. More specifically, extubation of the stent from the body can be achieved by grasping the filaments and pulling the stent out of the body via the urethra. This is most efficiently achieved in embodiments having filaments that are formed into loops, since an instrument can more readily grasp a loop than a single filament. The tensile strength of the filaments should be sufficient to prevent breakage of the filaments as the stent is being withdrawn from the body. If extubation is not a concern, filaments of reduced tensile strength, and hence of smaller diameter, can be used with the invention.


In some embodiments the pliable portion 135 comprises a distal end 138 of the plurality of filaments Ill, as illustrated in FIG. 15. The proximal region 106 includes a plurality of loops. Specifically, the proximal region 106 includes two loops 118 each formed from one continuous filament. Alternatively, the two loops 118 can be formed from a portion of four filaments 111; each loop can be formed from two filaments by joining them filaments together. A pliable portion 135 is formed from a portion of the flexible filaments 111 and is disposed adjacent to the proximal portion 137. The filaments 111 are configured to minimize any sharp exterior edges at the interface between the filaments and the junction of the distal portion 133, thus minimizing any potential irritation to the intramural ureter. The filaments 111 of the proximal portion 137 define an interstitial space 131. The lumen 260 of the tubular body 130 continues through to the pliable portion 135, as illustrated. Thus, the interstitial space 131 is in fluid communication with lumen 260, and provides for flow between the kidney and the bladder 20.


As illustrated in FIG. 15A, the filaments of the pliable portion 135 are compressible upon exertion of a pressure by the body, such as a pressure exerted by the ureteral orifice 18. In one embodiment, the stent is positioned within the body such that the filaments of the pliable portion 135 pass through the ureteral orifice 18 and extend distally into the ureter for a distance of approximately 2-3 centimeters. Because the proximal portion of the ureter is believed to be highly innervated, contact of this portion of the ureter with the softer material of the flexible filaments provides increased comfort to the patient.


Constriction of the ureteral orifice by the patient can exert a pressure on the filaments of the pliable portion 135 resulting in constriction, thereby reducing or eliminating the flow area through and about the interstitial space 131 of the proximal region 106 at the ureteral orifice 18. This reduction in flow area reduces or eliminates painful urine reflux that can be experienced by the patient upon voiding. In this way, the filaments of the pliable portion can be collapsed sufficiently to inhibit urine reflux. For example, FIG. 15B depicts a cross-sectional view taken at section B-B in FIG. 15. In this uncompressed state the flow area presented in interstitial space 131 is large. Upon constriction, e.g., by ureteral orifice 131, the flow area can be reduced as illustrated in FIG. 15C, representing a section taken at C-C of FIG. 15A. As can be seen from the figure, ureteral orifice 18 is contracted and the filaments 111 have been pressed closer to each other. In some embodiments, the filaments can be compressed to the point where some or all of them contact each other, as shown in FIGS. 15C′ and 15C″, further reducing or even eliminating the interstitial space 131.


The amount of interstitial space 131 remaining upon compression of the filaments can in part be determined by the physical properties of the filaments. In some embodiments, only partial compression of the interstitial space formed between the filaments 111 is achieved (e.g., FIG. 15C). In other embodiments, virtually all of the central interstitial space at a certain point along the length of the filaments can be eliminated by body pressure. In embodiments including filaments of an even softer material, flow area about the periphery of the filaments can also be eliminated or reduced (not shown). In many of these embodiments, urine flow through the ureteral orifice 18 can be virtually eliminated. It can be seen that upon the exertion of adequate force the filaments 111 not only contact each other, but if soft enough, they can be deformed by the pressure to further reduce any flow area. The ureteral stent of the invention thus allows urine flow reduction, including the reduction or elimination of urine reflux, to be achieved while minimizing irritation to the patient. When the pressure from the ureteral orifice is released, the filaments separate from each other thereby recreating the interstitial space.


In one embodiment, the overall length of the loops 118 in FIGS. 15 and 15A can be about 7-9 centimeters. Similar to the discussion above, a loop 118 with a length of 8 centimeters can be formed from a single filament 111 having a length of about 8 centimeters, or from two filaments 111 each having a length of about 8 centimeters. The loop 118 is designed to be sufficiently long to remain in the bladder 20 when the distal retention structure 104 is positioned within the kidney. In addition, the length should be sufficiently short to substantially reduce contact of the loop with the urethra 123, since contact with the urethra can cause patient discomfort. It can also result in obstruction of the flow of urine from the bladder through the prostatic urethra during voiding. Moreover, routine movement of the kidney and the bladder can result in corresponding relative motion along the stent length of about 2 centimeters. Proper sizing of the length of the filament loops can provide effective compensation for this movement. The length of the loop can be established to maintain at least a portion of the loop within the bladder after intubation, including upon routine movement of the kidney and the bladder. For this embodiment, a loop length of approximately 8 centimeters can be effective for this purpose.


Because contact of any portion of the proximal region 106 with the trigone also causes patient discomfort, such contact should be minimized or eliminated. Embodiments of the invention accomplish this by providing no significant retention force for the stent within the bladder 20. That is, the filaments 111 have a retention force insufficient to maintain the stent within the bladder. The flexible filaments are designed to free float within the bladder, making little or no contact with the trigone. Such contact is also minimized by having no stiffened or rigid areas within or about the filaments, and by minimizing their diameter, volume, surface area, and mass. Although the distal region of the stent can have a hardness of about 80-110 Shore A, the proximal region is generally much softer, having a Durometer hardness of approximately 60-80 Shore A. In some embodiments the hardness of the stent is gradually decreased from a distal location, e.g., 141, of the distal region to a proximal location, e.g., 142, of the proximal region. Preferably, the proximal region is integrally formed with the distal region in such embodiments.


The lower hardness limit (i.e., the softness limit) of the filaments 111 can be determined by the tensile strength required to withdraw the stent from the body. More specifically, extubation of the stent from the body can be achieved by grasping the filaments and pulling the stent out of the body via the urethra. This is most efficiently achieved in embodiments having filaments that are formed into loops, since an instrument can more readily grasp a loop than a single filament. The tensile strength of the filaments should be sufficient to prevent breakage of the filaments as the stent is being withdrawn from the body. If extubation is not a concern, filaments of reduced tensile strength, and hence of smaller diameter, can be used with the invention. Patient discomfort can thus be further reduced.



FIG. 16A illustrates placement of an embodiment of the invention within the body of a patient, in which the stent comprises two loops with a length of approximately 5 centimeters and a pliable portion including a soft portion or segment of tube compressible by body pressure. The distal retention structure 104 of the distal region 102 is located in the renal pelvis 19. The portion of the pliable portion 135 comprising the soft tube is encompassed by the ureteral orifice 18, and filaments of the proximal portion are disposed within the bladder 20. Loops 118 freely float within the bladder and have a length sufficient to maintain at least a portion of the filaments 111 within the bladder, including upon routine movement of the kidney and the bladder. The length of loops 118 is insufficient to contact the opening of the urethra 123.



FIG. 16B illustrates placement of an embodiment of the invention. The stent includes two loops (having a length, for example, of 8 centimeters) and a pliable portion including a portion of the flexible filaments compressible by body pressure. The distal retention structure 104 of the distal region 102 is located in the renal pelvis 19. The portion of the pliable portion 135 comprising the distal ends 138 of the flexible filaments 111 is encompassed by the ureteral orifice 18. Loops 118 freely float within the bladder and have a length sufficient to maintain at least a portion of the filaments 111 within the bladder, including upon routine movement of the kidney and the bladder. The length of loops 118 is insufficient to cross the bladder neck of the prostatic urethra 123.


Various fabrication and construction techniques can be used to manufacture embodiments of the ureteral stents of the invention. Construction of the stent 100 can include bonding a component that includes the proximal region 106, the distal region 102, and/or the filaments 111. The filaments 111 of the proximal region can be joined with the pliable portion 135 or with the distal region 102 via the junction 134 at the distal portion 133 (e.g., FIGS. 14 and 15).


Bonding of these components can be performed using heat-bonding techniques, such as by RF processes known in the art. Heat bonding functions by partially melting the plastic of a structure, allowing the melted plastic to adhere to a contacting surface or component, and allowing the plastic to cool and harden and thus form a bond. Heat bonding methods that include radio frequency bonding, induction heating and conduction heating may be used. The plastic of a first component may be selected to melt at a similar temperature as a second component so that both components are melted during the heat bonding process. Alternatively, either the first or second component may be constructed from plastic with a lower melting temperature than the other component in order that only the component with the lower melting temperature may melt during the bonding process. These techniques can also be used to form loops 118 by joining the proximal ends of two filaments 111. In embodiments comprising loops formed of one continuous filament, these techniques can be used to join the filaments with the pliable portion, the distal portion, the junction, or the tubular body.


Alternatively, the components may be bonded by the use of a bonding solvent, such as cyclohexanone and methylethylketone, for example. The bonding solvent acts by dissolving and swelling the plastic of the components. As the plastic of the components dissolve and swell, the components adhere to each other. The solvent is then removed allowing for the dissolved and swollen plastic to harden and thus complete the bonding process. These techniques can also be used to form loops 118 by joining the proximal ends of two filaments 111.


Embodiments can be fabricated from many different materials. Polymers and copolymers can be used and formed during the fabrication process, from materials such as polyurethane, polyamides, various thermoplastic elastomers, silicone, and various ethylene copolymers and block copolymers (e.g., ethyl vinyl acetate (EVA)). Other materials include biocompatible plastics, e.g., polyester, nylon based biocompatible polymers, polytetrafluoroethylene polymers, silicone polymers, polyurethane polymers, polyethylene polymers, and thermoplastic polymers. Combinations of these materials can be extruded or co extruded during the fabrication process. Portions of the stent can be made of materials with different Durometer hardness values, or the stent can be made such that the Durometer hardness value increases or decreases gradually from one location along the stent to another. In other embodiments, the entire stent can be formed of a very soft material such that the entire stent is formed from a material having a hardness of, for example, 60 Shore A.


The tubular portion of the stent may be manufactured by extruding a tube according to known techniques. The elongated tail (e.g., FIGS. 1-4) may be separately manufactured by conventional techniques and attached to the tubular portion, e.g., using biocompatible adhesive materials or heat. Alternatively, the stent may be made by injection molding the tube and the tail as a single piece, using a pin to create hollow segments. The stent may be manufactured from any of a number of biocompatible polymers commonly used inside the body, including polyurethane and polyethylene. In still other embodiments, the entire stent may be solid, so that urine is conveyed entirely on an external stent surface.


Another fabrication method, especially useful for embodiments such as those illustrated in FIGS. 13-16, includes forming, for example, four or twelve strands material into a tube. The strands can then be separated at the proximal end of the tube to form freefloating filaments for the proximal region. Loops can be formed from filaments by joining the proximal ends of two filaments with each other (although some embodiments include loops formed from one continuous filament). The joining can be performed using thermal and/or adhesive techniques. For example, the filaments can be joined with each other by positioning the materials in a mold and heating them together. These techniques can be used to join filament ends together, and to join filaments with the tube.


When fabrication techniques are used to join filaments to the tube, a mandrel can be inserted into the luminal portion of the device to maintain the luminal and/or interstitial space during heating. For example, a shaft size of 6 French can be used. A mold used with such a shaft should have a diameter that is 0.003-0.004 inches larger than the shaft diameter, to allow for insertion of the shaft, and to provide for molding of the filaments to the tube. The distal retention structure 104 can conveniently be formed from the tube.


In some embodiments the stent can be coated with a lubricious hydrophilic coating. Such a coating can be applied to the tubular body and/or the proximal region, to reduce the irritation levels attained through contact with the surrounding tissue/mucosa in the bladder. Care should be taken to ensure compatibility of the coating with any polymeric materials used.


Methods such as these can be used to produce embodiments with consistent and smooth exterior surfaces and outer diameters, for example, with diameters of 4-10 French.


Having thus described certain embodiments of the present invention, various alterations, modifications, and improvements will be apparent to those of ordinary skill. Such alterations, modifications, and improvements are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description of embodiments of the invention is not intended to be limiting.

Claims
  • 1. A ureteral stent, comprising: a tubular body defining a lumen, the tubular body being of a length that extends from a kidney of a patient to a portion of a ureter between a bladder of the patient and the kidney such that a proximal end of the tubular body terminates in the portion of the ureter between the bladder and the kidney, a distal region of the tubular body including a retention structure configured to help retain the ureteral stent within the kidney; andat least one filament extending from the proximal end of the tubular body, the at least one filament being of a length that extends from the portion of the ureter between the bladder and the kidney to a location within the bladder, wherein the at least one filament is configured to transfer fluid received from the proximal end of the tubular body to the bladder along a surface of the at least one filament.
  • 2. The ureteral stent of claim 1, wherein the proximal end of the tubular body defines an opening, the at least one filament being coupled to the proximal end via a loop through the opening of the proximal end of the tubular body.
  • 3. The ureteral stent of claim 1, wherein the at least one filament forms a loop.
  • 4. The ureteral stent of claim 1, wherein the filament forms a loop having a first portion extending monolithically from the proximal end of the tubular body and a second portion extending monolithically from the proximal end of the tubular body.
  • 5. The ureteral stent of claim 1, wherein the at least one filament includes multiple filaments forming multiple loops.
  • 6. The ureteral stent of claim 1, wherein the at least one filament forms a loop, a distal end of the loop extends distally from a ureteral orifice of the patient about 3 centimeters or more.
  • 7. The ureteral stent of claim 1, wherein the at least one filament forms a loop, the loop includes a pliable portion, the pliable portion being softer than a portion of the tubular body.
  • 8. The ureteral stent of claim 1, wherein the at least one filament forms a loop, the loop includes a pliable portion, the pliable portion is compressible upon an exertion of a pressure by a ureteral orifice of the patient.
  • 9. The ureteral stent of claim 1, wherein the at least one filament forms a loop, the loop includes a pliable portion, the pliable portion is configured to collapse sufficiently to inhibit urine reflux.
  • 10. The ureteral stent of claim 1, wherein the at least one filament forms a loop, and the loop is configured to transfer fluid along an interstitial space disposed between strands of the loop.
  • 11. The ureteral stent of claim 1, wherein the at least one filament forms a loop, the loop is configured to transfer fluid along an interstitial space disposed between strands of the loop, the interstitial space being at least partially collapsible upon exertion of body pressure.
  • 12. The ureteral stent of claim 1, wherein the at least one filament has a diameter less than approximately 0.040 inches.
  • 13. The ureteral stent of claim 1, wherein a hardness of the tubular body gradually decreases from a distal portion of the tubular body to the proximal end of the tubular body.
  • 14. The ureteral stent of claim 1, wherein the tubular body includes an opening on a surface of the tubular body, and the at least one filament includes a lumen, wherein the ureteral stent further includes a suture configured to extend through the opening and through the lumen of the at least one filament.
  • 15. A ureteral stent for assisting flow of urine, the stent comprising: an elongated tubular segment, the elongated tubular segment including a coiled end region configured to be positioned substantially in a kidney of a patient, the elongated tubular segment being of a length that extends from a kidney of a patient to a portion of a ureter between a bladder of the patient and the kidney such that the elongated tubular segment terminates in the portion of the ureter between the bladder and the kidney; anda flexible elongated tail extending monolithically from the proximal end of the elongated tubular segment, the flexible elongated tail including at least one thread being configured to extend from the portion of the ureter between the bladder and the kidney to a location within the bladder, wherein the at least one thread is configured to transfer fluid received from the proximal end of the elongated tubular segment to the bladder along a surface of the at least one filament.
  • 16. The stent of claim 15, wherein the flexible elongated tail includes multiple threads.
  • 17. The stent of claim 15, wherein the flexible elongated tail is solid.
  • 18. The stent of claim 15, wherein the flexible elongated tail is hollow.
  • 19. The stent of claim 15, wherein the elongated tubular segment includes multiple openings along its length.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of, and claims priority to, U.S. patent application Ser. No. 12/698,487, filed Feb. 2, 2010, entitled “Ureteral Stent for Improved Patient Comfort”, now U.S. Pat. No. 8,246,689, which is a continuation of U.S. patent application Ser. No. 11/327,409, filed Jan. 9, 2006, entitled “Ureteral Stent for Improved Patient Comfort,” now U.S. Pat. No. 7,678,154, which is a continuation of U.S. patent application Ser. No. 10/406,876, filed Apr. 4, 2003, entitled “Ureteral Stent for Improved Patient Care,” now U.S. Pat. No. 6,991,614, which is a continuation-in-part of U.S. patent application Ser. No. 09/849,202, filed May 4, 2001, now U.S. Pat. No. 6,676,623, and which is a continuation-in-part of U.S. patent application Ser. No. 09/300,657, filed on Apr. 27, 1999, now U.S. Pat. No. 6,656,146, which is a continuation of U.S. patent application Ser. No. 08/743,885, filed on Nov. 6, 1996, now U.S. Pat. No. 6,849,069, which claims priority to and the benefit of U.S. Patent Application Ser. No. 60/006,259 filed Nov. 7, 1995, U.S. Patent Application Ser. No. 60/009,983, filed Jan. 16, 1996 and U.S. Patent Application Ser. No. 60/025,284, filed Sep. 19, 1996, the contents of each of these applications are incorporated herein by reference in their entirety.

US Referenced Citations (349)
Number Name Date Kind
191775 Parsons Jun 1877 A
256590 Pfarre Apr 1882 A
386603 Parsons Jul 1888 A
559620 Shearer May 1896 A
1211928 Fisher Jan 1917 A
2257369 Davis Sep 1941 A
3087493 Schossow Apr 1963 A
3314430 Alley et al. Apr 1967 A
3359974 Khalil Dec 1967 A
3394705 Abramson Jul 1968 A
3437088 Bielinski Apr 1969 A
3485234 Stevens Dec 1969 A
3593713 Bogoff et al. Jul 1971 A
3612050 Sheridan Oct 1971 A
3633579 Alley et al. Jan 1972 A
3726281 Norton et al. Apr 1973 A
3746003 Blake et al. Jul 1973 A
3788326 Jacobs Jan 1974 A
3828767 Spiroff Aug 1974 A
3902492 Greenhalgh Sep 1975 A
3906954 Baehr et al. Sep 1975 A
3920023 Dye et al. Nov 1975 A
3995623 Blake et al. Dec 1976 A
4004588 Alexander Jan 1977 A
4037599 Raulerson Jul 1977 A
4065264 Lewin Dec 1977 A
4069814 Clemens Jan 1978 A
4096860 McLaughlin Jun 1978 A
4099528 Sorenson et al. Jul 1978 A
4100246 Frisch Jul 1978 A
4129129 Amrine Dec 1978 A
4134402 Marhurkar Jan 1979 A
4138288 Lewin Feb 1979 A
4138457 Rudd et al. Feb 1979 A
4144884 Tersteegen et al. Mar 1979 A
4149535 Volder Apr 1979 A
4168703 Kenigsberg Sep 1979 A
4173981 Mortensen Nov 1979 A
4180068 Jacobsen et al. Dec 1979 A
4182739 Curtis Jan 1980 A
4183961 Curtis Jan 1980 A
4202332 Tersteegen et al. May 1980 A
4203436 Grimsrud May 1980 A
4204541 Kapitanov May 1980 A
4212304 Finney Jul 1980 A
4217895 Sagae et al. Aug 1980 A
4223676 Wuchinich et al. Sep 1980 A
4236520 Anderson Dec 1980 A
4239042 Asai Dec 1980 A
4243040 Beecher Jan 1981 A
4257416 Prager Mar 1981 A
4270535 Bogue et al. Jun 1981 A
4307723 Finney Dec 1981 A
4327722 Groshong et al. May 1982 A
4334327 Lyman et al. Jun 1982 A
4385631 Uthmann May 1983 A
4403983 Edelman et al. Sep 1983 A
4405313 Sisley et al. Sep 1983 A
4405314 Cope Sep 1983 A
4406656 Hattler et al. Sep 1983 A
4413989 Schjeldahl et al. Nov 1983 A
4419094 Patel Dec 1983 A
D272651 Marhurkar Feb 1984 S
4443333 Marhurkar Apr 1984 A
4451252 Martin May 1984 A
4456000 Schjeldahl et al. Jun 1984 A
4484585 Baier Nov 1984 A
4493696 Uldall Jan 1985 A
4504264 Kelman Mar 1985 A
RE31873 Howes Apr 1985 E
4531933 Norton et al. Jul 1985 A
4540402 Aigner Sep 1985 A
4543087 Sommercom et al. Sep 1985 A
4559046 Groshong et al. Dec 1985 A
4563170 Aigner Jan 1986 A
4568329 Marhurkar Feb 1986 A
4568338 Todd Feb 1986 A
4581012 Brown et al. Apr 1986 A
4583968 Marhurkar Apr 1986 A
4596548 DeVries et al. Jun 1986 A
4601697 Mammolenti et al. Jul 1986 A
4601701 Mueller, Jr. Jul 1986 A
4608993 Albert Sep 1986 A
4610657 Densow Sep 1986 A
4619643 Bai Oct 1986 A
4623327 Marhurkar Nov 1986 A
4626240 Edelman et al. Dec 1986 A
4641652 Hutterer et al. Feb 1987 A
4643711 Bates Feb 1987 A
4643716 Drach Feb 1987 A
4648865 Aigner Mar 1987 A
4655771 Wallsten Apr 1987 A
4666426 Aigner May 1987 A
4671795 Mulchin Jun 1987 A
4675004 Hadford et al. Jun 1987 A
4682978 Martin Jul 1987 A
4687471 Twardowski et al. Aug 1987 A
4692141 Marhurkar Sep 1987 A
4694838 Wijayarthna et al. Sep 1987 A
4713049 Carter Dec 1987 A
4722725 Sawyer et al. Feb 1988 A
4732152 Wallsten et al. Mar 1988 A
4737146 Amaki et al. Apr 1988 A
4738667 Galloway Apr 1988 A
4747840 Ladika et al. May 1988 A
4753640 Nichols et al. Jun 1988 A
4755176 Patel Jul 1988 A
4769005 Ginsburg et al. Sep 1988 A
4770652 Marhurkar Sep 1988 A
4772268 Bates Sep 1988 A
4773432 Rydell Sep 1988 A
4776841 Catalano Oct 1988 A
4782834 Maguire et al. Nov 1988 A
4787884 Goldberg Nov 1988 A
4790809 Kuntz Dec 1988 A
4790810 Pugh, Jr. et al. Dec 1988 A
4795439 Guest Jan 1989 A
4808155 Marhurkar Feb 1989 A
4809710 Williamson Mar 1989 A
4813429 Eshel et al. Mar 1989 A
4813925 Anderson et al. Mar 1989 A
4820262 Finney Apr 1989 A
4822345 Danforth Apr 1989 A
4838881 Bennett Jun 1989 A
4842582 Marhurkar Jun 1989 A
4842590 Tanabe et al. Jun 1989 A
4846791 Hattler et al. Jul 1989 A
4846814 Ruiz Jul 1989 A
4863424 Blake, III et al. Sep 1989 A
4863442 DeMello et al. Sep 1989 A
4865595 Heyden Sep 1989 A
4874360 Goldberg et al. Oct 1989 A
4887996 Bengmark Dec 1989 A
4894057 Howes Jan 1990 A
4895561 Marhurkar Jan 1990 A
4913683 Gregory Apr 1990 A
4931037 Wetterman Jun 1990 A
4950228 Knapp, Jr. et al. Aug 1990 A
4954126 Wallsten Sep 1990 A
4960409 Catalano Oct 1990 A
4960411 Buchbinder Oct 1990 A
4961809 Martin Oct 1990 A
4963129 Rusch Oct 1990 A
4973301 Nissenkorn Nov 1990 A
4978341 Niederhauser Dec 1990 A
4981482 Ichikawa Jan 1991 A
4983169 Furukawa Jan 1991 A
4985022 Fearnot et al. Jan 1991 A
4986814 Burney et al. Jan 1991 A
4990133 Solazzo Feb 1991 A
4994071 MacGregor Feb 1991 A
4995863 Nichols et al. Feb 1991 A
4995865 Gahara et al. Feb 1991 A
4995868 Brazier Feb 1991 A
4998919 Schnepp-Pesch et al. Mar 1991 A
5009636 Wertley et al. Apr 1991 A
5013296 Buckberg et al. May 1991 A
5019102 Hoene May 1991 A
5026377 Burton et al. Jun 1991 A
5029580 Radford et al. Jul 1991 A
5041083 Tsuchida et al. Aug 1991 A
5045072 Castillo et al. Sep 1991 A
5052998 Zimmon Oct 1991 A
5053004 Markel et al. Oct 1991 A
5053023 Martin Oct 1991 A
5057073 Martin Oct 1991 A
5061275 Wallsten et al. Oct 1991 A
5069673 Shwab Dec 1991 A
5078720 Burton et al. Jan 1992 A
5098440 Hillstead Mar 1992 A
5116309 Coll May 1992 A
5124127 Jones et al. Jun 1992 A
5129910 Phan et al. Jul 1992 A
5135487 Morrill et al. Aug 1992 A
5135599 Martin et al. Aug 1992 A
5141499 Zappacosta Aug 1992 A
5141502 Macaluso, Jr. Aug 1992 A
5147370 McNamara et al. Sep 1992 A
5149330 Brightbill Sep 1992 A
5156592 Martin et al. Oct 1992 A
5156596 Balbierz et al. Oct 1992 A
5160325 Nichols et al. Nov 1992 A
5167623 Cianci et al. Dec 1992 A
5171216 Dasse et al. Dec 1992 A
5176625 Brisson Jan 1993 A
5176626 Soehendra Jan 1993 A
5178803 Tsuchida et al. Jan 1993 A
5188593 Martin Feb 1993 A
5190520 Fenton, Jr. et al. Mar 1993 A
5195962 Martin et al. Mar 1993 A
5197951 Marhurkar Mar 1993 A
5205830 Dassa et al. Apr 1993 A
5207648 Gross May 1993 A
5209723 Twardowski et al. May 1993 A
5211627 William May 1993 A
5221253 Coll Jun 1993 A
5221255 Marhurkar et al. Jun 1993 A
5221256 Marhurkar Jun 1993 A
5224953 Morgentaler Jul 1993 A
5234663 Jones et al. Aug 1993 A
5240677 Jones et al. Aug 1993 A
5242395 Maglinte Sep 1993 A
5246445 Yachia et al. Sep 1993 A
5250034 Appling et al. Oct 1993 A
5250038 Melker et al. Oct 1993 A
5261879 Brill Nov 1993 A
5269802 Garber Dec 1993 A
5275597 Higgins et al. Jan 1994 A
5279560 Morrill et al. Jan 1994 A
5282784 Willard Feb 1994 A
5292305 Boudewijn et al. Mar 1994 A
5295954 Sachse Mar 1994 A
5308322 Tennican et al. May 1994 A
5318532 Frassica Jun 1994 A
5324274 Martin Jun 1994 A
5330449 Prichard et al. Jul 1994 A
5330483 Heaven et al. Jul 1994 A
5338311 Marhurkar Aug 1994 A
5342301 Saab Aug 1994 A
5342387 Summers Aug 1994 A
5344412 Wendell et al. Sep 1994 A
5346467 Coll Sep 1994 A
5346471 Raulerson Sep 1994 A
5348536 Young et al. Sep 1994 A
5354263 Coll Oct 1994 A
5354309 Schnepp-Pesch et al. Oct 1994 A
5356423 Tihon et al. Oct 1994 A
5356424 Buzerak et al. Oct 1994 A
5358689 Jones et al. Oct 1994 A
5360397 Pinchuk Nov 1994 A
5364340 Coll Nov 1994 A
5364344 Beattie et al. Nov 1994 A
5366464 Belknap Nov 1994 A
5372600 Beyar et al. Dec 1994 A
5374245 Marhurkar Dec 1994 A
5378230 Marhurkar Jan 1995 A
5380270 Ahmadzadeh Jan 1995 A
5380276 Miller et al. Jan 1995 A
5383928 Scott et al. Jan 1995 A
5391196 Devonee Feb 1995 A
5395316 Martin Mar 1995 A
5399172 Martin et al. Mar 1995 A
5401257 Chevalier, Jr. et al. Mar 1995 A
5403291 Abrahamson Apr 1995 A
5405320 Twardowski et al. Apr 1995 A
5405329 Durand Apr 1995 A
5405341 Martin Apr 1995 A
5405380 Gianotti et al. Apr 1995 A
5411490 Tennican et al. May 1995 A
5440327 Stevens Aug 1995 A
5441515 Khosravi et al. Aug 1995 A
5449372 Schmaltz et al. Sep 1995 A
5451206 Young Sep 1995 A
5454790 Dubrul Oct 1995 A
5464398 Haindl Nov 1995 A
5470322 Horzewski et al. Nov 1995 A
5472417 Martin et al. Dec 1995 A
5472432 Martin Dec 1995 A
5480380 Martin Jan 1996 A
5486159 Mahurkar Jan 1996 A
5489278 Abrahamson Feb 1996 A
5509897 Twardowski et al. Apr 1996 A
5509900 Kirkman Apr 1996 A
5514100 Marhurkar May 1996 A
5514176 Bosley, Jr. May 1996 A
5514178 Torchio May 1996 A
5520697 Lindenberg et al. May 1996 A
5522807 Luther Jun 1996 A
5527337 Stack et al. Jun 1996 A
5531741 Barbacci Jul 1996 A
5540713 Schnepp-Pesch et al. Jul 1996 A
5554136 Luther Sep 1996 A
5554147 Batich et al. Sep 1996 A
5556390 Hicks Sep 1996 A
5562641 Flomenblit et al. Oct 1996 A
5569182 Twardowski et al. Oct 1996 A
5569184 Crocker et al. Oct 1996 A
5569195 Saab Oct 1996 A
5571093 Cruz et al. Nov 1996 A
5573508 Thornton Nov 1996 A
5599291 Balbierz et al. Feb 1997 A
5599306 Klein et al. Feb 1997 A
5609627 Coicoechea et al. Mar 1997 A
5613980 Chauhan Mar 1997 A
5624395 Mikhail et al. Apr 1997 A
5624413 Markel et al. Apr 1997 A
5630794 Lax et al. May 1997 A
5639278 Dereume et al. Jun 1997 A
5643222 Marhurkar Jul 1997 A
5647843 Mesrobian et al. Jul 1997 A
5647858 Davidson Jul 1997 A
5649909 Cornelius Jul 1997 A
5653689 Buelna et al. Aug 1997 A
5667486 Mikulich et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5676697 McDonald Oct 1997 A
5681274 Perkins et al. Oct 1997 A
5683640 Miller et al. Nov 1997 A
5685862 Marhurkar Nov 1997 A
5685867 Twardowski et al. Nov 1997 A
5695479 Jagpal Dec 1997 A
5700286 Tartalin et al. Dec 1997 A
5707386 Schnepp-Pesch et al. Jan 1998 A
5723003 Winston et al. Mar 1998 A
5766209 Devonec Jun 1998 A
5769868 Yock Jun 1998 A
5776161 Globerman Jul 1998 A
5792105 Lin et al. Aug 1998 A
5792400 Talja et al. Aug 1998 A
5795319 Ali Aug 1998 A
5795326 Siman Aug 1998 A
5814006 Planz Sep 1998 A
5830179 Mikus et al. Nov 1998 A
5830184 Basta Nov 1998 A
5830196 Hicks Nov 1998 A
5843028 Weaver et al. Dec 1998 A
5860999 Schnepp-Pesch et al. Jan 1999 A
5865815 Tihon Feb 1999 A
5868718 Pepin et al. Feb 1999 A
5876417 Devonec et al. Mar 1999 A
5906640 Penn et al. May 1999 A
5922443 Larsen et al. Jul 1999 A
5928217 Mikus et al. Jul 1999 A
5964771 Beyar et al. Oct 1999 A
6033413 Mikus et al. Mar 2000 A
6139536 Mikus et al. Oct 2000 A
6146396 Konya et al. Nov 2000 A
6197014 Samson et al. Mar 2001 B1
6206849 Martin et al. Mar 2001 B1
6248100 de Toledo et al. Jun 2001 B1
6258098 Taylor et al. Jul 2001 B1
6283991 Cox et al. Sep 2001 B1
6306105 Rooney et al. Oct 2001 B1
6332892 Desmond, III et al. Dec 2001 B1
6334868 Ham Jan 2002 B1
6371953 Beyar et al. Apr 2002 B1
6395021 Hart et al. May 2002 B1
6450987 Kramer Sep 2002 B1
6458145 Ravenscroft et al. Oct 2002 B1
6558350 Hart et al. May 2003 B1
6569150 Teague et al. May 2003 B2
6656146 Clayman et al. Dec 2003 B1
6676623 Whitmore, III Jan 2004 B2
6764519 Whitmore, III Jul 2004 B2
6849069 Clayman et al. Feb 2005 B1
6945950 Clayman et al. Sep 2005 B2
6991614 McWeeney et al. Jan 2006 B2
7678154 McWeeney et al. Mar 2010 B2
8246689 McWeeney et al. Aug 2012 B2
Foreign Referenced Citations (54)
Number Date Country
1092927 Jan 1981 CA
1150122 Jul 1983 CA
1167727 May 1984 CA
1193508 Sep 1985 CA
1219785 Mar 1987 CA
1225299 Nov 1987 CA
2259865 Jun 1974 DE
3112762 Jan 1983 DE
3517813 Nov 1986 DE
3740288 Apr 1989 DE
4103573 Aug 1992 DE
4134030 Apr 1993 DE
4213480 Oct 1993 DE
9314585 Jan 1994 DE
9314585.3 Mar 1994 DE
0036642 Sep 1981 EP
0079719 May 1983 EP
0101890 Mar 1984 EP
0144525 Jun 1985 EP
0168136 Jan 1986 EP
0183421 Jun 1986 EP
0101890 Sep 1986 EP
0326908 Aug 1989 EP
0333308 Sep 1989 EP
0183421 Apr 1990 EP
0386408 Sep 1990 EP
0490459 Jun 1992 EP
0490459 Jun 1992 EP
0554722 Aug 1993 EP
0554722 Aug 1993 EP
0806189 May 1997 EP
0876803 Nov 1998 EP
1285953 Jan 1962 FR
1508959 Dec 1967 FR
2297640 Aug 1976 FR
2530958 Feb 1984 FR
2611486 Sep 1988 FR
2017499 Oct 1979 GB
2156220 Oct 1985 GB
2235384 Mar 1991 GB
57-90150 Jun 1982 JP
62-20830 Aug 1994 JP
8404043 Oct 1984 WO
9526763 Oct 1995 WO
9535130 Dec 1995 WO
96-11721 Apr 1996 WO
96-11721 Apr 1996 WO
9710858 Feb 1997 WO
9710858 Mar 1997 WO
9117094 May 1997 WO
9717094 May 1997 WO
9737699 Oct 1997 WO
9737718 Oct 1997 WO
02098500 Dec 2002 WO
Non-Patent Literature Citations (60)
Entry
Bard product brochure, “Stents to SatisfY the Urologist: . . . ”, 1988.
Bard product brochure, “Introducing the Bard Pediatric Urethral Stent,” 1983.
Cook Critical Care Catalog, “Products for Dialysis,” 1989, pp. 3-15.
McIntosh, el a/. “Double lumen Catheter for Use With Artificial Kidney,” 1959, J.A.M.A. /69(8):131-8.
Quinton Instrument Co. Catalog, “Hemodialysis and Apheresis” (1994).
Quinton Instrument Co. Catalog, “Hemodialysis and Apheresis” (1995).
Quinton Instrument Co. Catalog, “Oncology/Critical Care” (1993).
Riesenfeld, et al “Surface Modification of Functionally Active Heparin,” Medical Device Technology. Mar. 1995.
“Triple Lumen Catheter” p. 3 {First! An Information Service of Individual, Inc., Sep. 25, 1995).
International Search Repon for International Patent Application No. PCT|US02/13918, dated Oct. 9, 2002, 5 pgs.
International Search Report for International Patent Application No. PCT|US03/11879, dated Dec. 23, 2003.
Office Action for EP Application No. 10184665.7, mailed Nov. 25, 2011, 3 pages.
Office Action Response for EP Application No. 10184665.7, filed Mar. 14, 2012,4 pages.
Extended European Search Report for European Application No. 10184665.7, mailed on Jan. 24, 2011, 4 pages.
Notice of Allowance for U.S. Appl. No. 08/743,885, mailed on Mar. 16, 1999,4 pages.
Office Action for U.S. Appl. No. 08/743,885, mailed on Nov. 9, 2001, 7 pages.
Office Action for U.S. Appl. No. 08/743,885, mailed on May 8, 2001, 8 pages.
Office Action for U.S. Appl. No. 08/743,885, mailed on Feb. 17, 1999,4 pages.
Office Action for U.S. Appl. No. 08/743,885, mailed on Jul. 5, 2000, 5 pages.
Supplemental Notice of Allowability for U.S. Appl. No. 08/743,885, mailed on Aug. 3, 1999, 2 pages.
Notice of Allowance for U.S. Appl. No. 08/743,885, mailed on Jul. 25, 2002, 4 pages.
Office Action for U.S. Appl. No. 09/849,202, mailed on Jun. 17, 2003, 7 pages.
Office Action for U.S. Appl. No. 08/743,885, mailed on Apr. 24, 2002, 10 pages.
Office Action for U.S. Appl. No. 09/849,202, mailed on Jan. 22, 2003, 10 pages.
Supplemental Notice of Allowability for U.S. Appl. No. 09/300,657, mailed on Sep. 16, 2003, 15 pages.
Office Action for U.S. Appl. No. 09/849,202, mailed on Sep. 30, 2002, 13 pages.
Notice of Allowance for U.S. Appl. No. 09/849,202, mailed on Aug. 25, 2003, 6 pages.
Office Action for U.S. Appl. No. 09/300,657, mailed on Aug. 16, 2000, 10 pages.
Notice of Allowance for U.S. Appl. No. 09/300,657, mailed on Jun. 17, 2003, 13 pages.
Office Action for U.S. Appl. No. 09/300,657, mailed on May 23, 2001, 9 pages.
Office Action for U.S. Appl. No. 09/300,657, mailed on Mar. 24, 2003, 8 pages.
Office Action for U.S. Appl. No. 09/300,657, mailed on Oct. 23, 2001, 6 pages.
Office Action for U.S. Appl. No. 09/300,657, mailed on Aug. 28, 2002, 8 pages.
Office Action for U.S. Appl. No. 09/300,657, mailed on May 9, 2002, 8 pages.
Mardis et al, “Comparative Evaluation of Materials Used for Internal Ureteral Stents,” Journal or Endourology, 1993, vol. 7, No. 2, pp. 105-115.
“Ureteroscopic Procedures—Technical Advances,” Color Alias/Text of Ureteroscopy, 1993 New York, Igaku-Shoin, p. 281.
Collier, et al, “Proximal Stent Displacement as Complication of Pigtail Ureteral Stent”, Urology, Apr. 1979, vol. XIII, No. 4, pp. 372-375.
Birch et al., “Tethered Ureteric Stents—a Clinical Assessment,” British Journal of Urology, 1988, 62, pp. 409-411.
Cook Urological product brochure, “Ureteral Stents”, 1987, pp. 1-12; last page.
Cook Urological catalog, “Urological Surgical Product”, 1990-1991, pp. 1-3, 7-29, 48-148; last page.
Bard/angiorned product brochure, 1988.
Cook Urological Catalog, 1995, pp. 1-2, 9-41, 63-173; last page.
Mardis, et al, “Ureteral Stents—Materials”, Urological Clinics of North America, Aug. 1988, vol. 15, No. 3, pp. 471-479.
Mardis, et al., “Ureteral Stents Use and Complications”, Problems in Urology, Jun. 1992, vol. 6, No. 2, pp. 296-306.
Hackethorn et al.,“Antegrade Internal Ureteral Stenting: A Technical Refinement,” Radiology, Jul. 1985, vol. 156, No. 3, pp. 827-828.
Rutner et al., “Percutaneous Pigtail Nephrostomy,” Urology, Oct. 1979, vol. XIV, No. 4, pp. 337-340.
Mardis, “Evaluation of Polymeric Materials for Endourologic Devices,” Seminars in Interventional Radjology, Mar. 1987, vol. 4, No. I, pp. 36-45.
Mardis et al., “Double Pigtail Ureteral Stent,” Urology, Jul. 1979, vol. XIV, No. I, pp. 23-26.
Hepperlen et al., “Self-Retained Internal Ureteral Stents: A New Approach,” The Journal of Urology, Jun. 1978, vol. 119, pp. 731-734.
Cuikin, “Complications of Ureteral Stents,” Infections in Urology, Sep./Oct. 1996, pp. 139-143.
Sadiowski eta al., “New Technique for Percutaneous Nephrostomy Under Ultrasound Guidance,” Journal of Urology, May 1979, vol. 121, pp. 559-561.
Camacho et at. “Double-Ended Pigtail Ureteral Stent: Useful Modification to Single End Ureteral Stent,” Urology, May 1979, vol. XIII, No. 5, pp. 516-520.
Bigongiari et al., “Conversion of Percutaneous Ureteral Stent to Indwelling Pigtail Stent Over Guidewire,” Urology, May 1980, vol. XV, No. 5, pp. 461-465.
Minkov et al, “Our Experience in the Application of the Biocompatible Indwelling Ureteral Stents,” International Urology and Nephrology, 1986, 18 (4), pp. 403-409.
Mardis eta!., “Polyethylene Double-Pigtail Ureteral Stents,” Urologic Clinics of North America, Feb. 1982, vol. 9, No. I, pp. 95-101.
Stables, “Percutaneous Nephrostomy: Techniques, Indications, and Results,” Urologic Clinics of North America, Feb. 1982, vol. 9, No. I, pp. 15-29.
Bard Urological Division product catalog, 1990, pp. I-3, AI-A30, D7-D26; last page.
Cook Urological product brochure, “Filiform Ureteral Multi-Length Silicone Stent Sets,” 1989.
Surgitek brochure, “The Solution Is Perfectly Clear,” 1990.
Bard brochure, “Introducing the Bard Urinary Diversion Stent,” 1984.
Related Publications (1)
Number Date Country
20130024003 A1 Jan 2013 US
Provisional Applications (3)
Number Date Country
60006259 Nov 1995 US
60009983 Jan 1996 US
60025284 Sep 1996 US
Continuations (4)
Number Date Country
Parent 12698487 Feb 2010 US
Child 13559224 US
Parent 11327409 Jan 2006 US
Child 12698487 US
Parent 10406876 Apr 2003 US
Child 11327409 US
Parent 08743885 Nov 1996 US
Child 09300657 US
Continuation in Parts (2)
Number Date Country
Parent 09849202 May 2001 US
Child 10406876 US
Parent 09300657 Apr 1999 US
Child 09849202 US